Full Press Release Details
NANOBIOTIX to Participate in Two Upcoming Investor Conferences
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2022--Regulatory News:
NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the "Company"), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy,
co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the following conferences:
UBS Global Healthcare Conference
Presentation Date: Monday, May 23rd, 2022
Location: New York, New York, USA
H.C. Wainwright Global Investment Conference
Presentation Date: Wednesday, May 25th, 2022
Location: Virtual and Miami, Florida, USA
A live audio webcast of each presentation will be available on the events page of the Investors section of the Company's website. A replay will be available on the Nanobiotix website within 48 hours after each event. The Company's corporate
presentation can be downloaded here.
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for
humanity. The company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany.
Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.
Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The
company's resources are primarily devoted to the development of its lead product candidate- NBTXR3 -which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients
with soft tissue sarcoma under the brand name Hensify .
Contacts
Communications Department
Investor Relations Department
SVP, Investor Relations
FR - Ulysse Communication
Pierre-Louis Germain
+33 (0) 6 64 79 97 51